300122 智飞生物
已收盘 08-14 15:00:00
资讯
新帖
简况
智飞生物：专一专注专业深耕生物制药领域
证券之星 · 08-14 17:06
智飞生物：专一专注专业深耕生物制药领域
智飞生物：聚焦生产经营稳健发展
证券之星 · 08-14 17:06
智飞生物：聚焦生产经营稳健发展
智飞生物：公司专一、专注、专业地在生物制药领域深耕
证券之星 · 08-14 17:06
智飞生物：公司专一、专注、专业地在生物制药领域深耕
智飞生物：截至2026年8月10日股东人数为113,869
证券之星 · 08-14 17:06
智飞生物：截至2026年8月10日股东人数为113,869
智飞生物：通过三大研产基地完善“预防&治疗”一体化布局
证券之星 · 08-14 17:03
智飞生物：通过三大研产基地完善“预防&治疗”一体化布局
智飞生物最新公告：鼻喷重组RSV疫苗临床试验申请获受理
证券之星 · 08-10
智飞生物最新公告：鼻喷重组RSV疫苗临床试验申请获受理
智飞生物(300122)7月31日股东户数11.4万户，较上期减少0.29%
证券之星 · 08-07
智飞生物(300122)7月31日股东户数11.4万户，较上期减少0.29%
智飞生物：CA111注射液处于一期临床试验阶段
证券之星 · 08-07
智飞生物：CA111注射液处于一期临床试验阶段
智飞生物：截至2026年7月31日，公司普通股股东人数为114,012
证券之星 · 08-07
智飞生物：截至2026年7月31日，公司普通股股东人数为114,012
股市必读：智飞生物新发布《关于回购公司股份的进展公告》
证券之星 · 08-04
股市必读：智飞生物新发布《关于回购公司股份的进展公告》
股市必读：智飞生物（300122）7月31日董秘有最新回复
证券之星 · 08-03
股市必读：智飞生物（300122）7月31日董秘有最新回复
智飞生物：聚焦糖尿病、肥胖等代谢类疾病领域
证券之星 · 07-31
智飞生物：聚焦糖尿病、肥胖等代谢类疾病领域
智飞生物：宸安生物利拉鲁肽注射液获批上市
证券之星 · 07-31
智飞生物：宸安生物利拉鲁肽注射液获批上市
智飞生物：截至2026年7月20日，公司普通股股东人数为114,348
证券之星 · 07-24
智飞生物：截至2026年7月20日，公司普通股股东人数为114,348
智飞生物最新公告：拟以1.5亿元至3亿元回购公司股份
证券之星 · 07-20
智飞生物最新公告：拟以1.5亿元至3亿元回购公司股份
智飞生物：公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局
证券之星 · 07-17
智飞生物：公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局
智飞生物：开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发
证券之星 · 07-17
智飞生物：开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发
智飞生物：聚焦生产经营稳健发展
证券之星 · 07-17
智飞生物：聚焦生产经营稳健发展
智飞生物：自主产品涵盖预防流脑、流感等传染病的疫苗
证券之星 · 07-17
智飞生物：自主产品涵盖预防流脑、流感等传染病的疫苗
智飞生物最新公告：控股子公司利拉鲁肽注射液获药品注册证书
证券之星 · 07-10
智飞生物最新公告：控股子公司利拉鲁肽注射液获药品注册证书
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":13.06,"timestamp":1786691025000,"preClose":13.22,"halted":0,"volume":27734443,"delay":0,"changeRate":-0.0121,"floatShares":1414000000,"shares":2394000000,"eps":-6.1778,"marketStatus":"已收盘","change":-0.16,"latestTime":"08-14 15:00:00","open":13.1,"high":13.31,"low":12.9,"amount":362000000,"amplitude":0.031,"askPrice":13.07,"askSize":922,"bidPrice":13.06,"bidSize":959,"shortable":0,"etf":0,"ttmEps":-6.1778,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"adjPreClose":13.22,"symbolType":"stock","openAndCloseTimeList":[[1786671000000,1786678200000],[1786683600000,1786690800000]],"highLimit":14.54,"lowLimit":11.9,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":2.05,"roa":"--","roe":"--","epsLYR":-6.1506,"committee":0.106367,"marketValue":31263000000,"turnoverRate":0.0196,"status":1,"floatMarketCap":18471000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2659296112","title":"智飞生物：专一专注专业深耕生物制药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2659296112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659296112?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:06","pubTimestamp":1786698388,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，近期生物制药领域各大公司股价都大幅上涨，贵公司股价却停滞不前，其原因是什么？该如何扭转当前局面？智飞生物回复：您好，二级市场股票价格受多种因素影响。公司专一、专注、专业地在生物制药领域深耕，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。公司的发展情况请您关注公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400028168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0077","BK0046","LU2580892789.USD","LU2580892862.HKD","LU1064131003.USD","BK0188","03069","LU1064130708.USD","BK0239","LU2148510915.USD","LU1328615791.USD","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112257","title":"智飞生物：聚焦生产经营稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659112257?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:06","pubTimestamp":1786698386,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，根据智飞长期在股票市场的表现，是否可以考虑主动申请退市？安心做产品研究开发。这样对公司对投资者都是比较中肯的选择，因为公司已经不具备跟同行业的大中小公司的竞争能力。智飞生物回复：您好，公司聚焦生产经营稳健发展，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。公司的发展情况请您关注公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400028163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","300122","LU1064131003.USD","LU2148510915.USD","LU2580892862.HKD","BK0077","LU2580892789.USD","BK0188","LU1328615791.USD","LU1064130708.USD","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659111226","title":"智飞生物：公司专一、专注、专业地在生物制药领域深耕","url":"https://stock-news.laohu8.com/highlight/detail?id=2659111226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659111226?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:06","pubTimestamp":1786698384,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，市场很多投资者因为选择投资智飞生物而后悔不已，这种消极的情绪和言传口碑，是否会直接或间接影响公司产品在全国各地的销售？针对这种连锁负反馈，公司是否制定相关措施来制止或弥补这一情况的发生？！请详细回答一下智飞生物回复：您好，二级市场股票价格受多种因素影响。公司专一、专注、专业地在生物制药领域深耕，为民众提供优质产品。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400028160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","LU1064130708.USD","LU2580892862.HKD","03069","BK0046","LU2148510915.USD","BK0077","LU1328615791.USD","BK0188","LU2580892789.USD","BK0239","LU1064131003.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659211223","title":"智飞生物：截至2026年8月10日股东人数为113,869","url":"https://stock-news.laohu8.com/highlight/detail?id=2659211223","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659211223?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:06","pubTimestamp":1786698378,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月14日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！敬请发布截至今天收盘公司8月上旬末的股东户数信息。谢谢！致礼！智飞生物回复：您好，截至2026年8月10日，公司普通股股东人数为113,869，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400028153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","LU2580892789.USD","LU1328615791.USD","LU1064130708.USD","LU2148510915.USD","LU2580892862.HKD","BK0196","LU1064131003.USD","300122","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112647","title":"智飞生物：通过三大研产基地完善“预防&治疗”一体化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112647","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659112647?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:03","pubTimestamp":1786698199,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，目前公司在生物制药领域，从规模，技术，销售范围，是否属于龙头公司？能够引领行业发展智飞生物回复：您好，公司通过北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地持续完善“预防&治疗”一体化布局。同时，公司参股重庆智睿投资有限公司，积极布局大健康领域，促进前沿生物医药、先进生物技术的研发和产业化。公司的研发管线详情请您查阅公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400028000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1328615791.USD","BK0196","BK0046","300122","BK0188","BK0239","LU1064130708.USD","LU2580892789.USD","LU2580892862.HKD","LU1064131003.USD","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658980685","title":"智飞生物最新公告：鼻喷重组RSV疫苗临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980685","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658980685?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:39","pubTimestamp":1786358375,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司全资子公司智飞绿竹研发的鼻喷重组呼吸道合胞病毒疫苗(黑猩猩腺病毒载体)获国家药监局临床试验申请受理通知书。该疫苗拟用于预防RSV引起的下呼吸道感染，通过鼻喷免疫诱导呼吸道黏膜免疫应答。截至公告日，国内尚无RSV疫苗获批上市。若项目进展顺利，将与公司现有呼吸道疫苗布局形成协同效应。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000026501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0077","LU2580892789.USD","LU2580892862.HKD","LU1064130708.USD","LU1328615791.USD","BK0239","159646","300122","LU2148510915.USD","BK0188","LU1064131003.USD","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657611249","title":"智飞生物(300122)7月31日股东户数11.4万户，较上期减少0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657611249","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657611249?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:40","pubTimestamp":1786095606,"startTime":"0","endTime":"0","summary":"证券之星消息，近日智飞生物披露，截至2026年7月31日公司股东户数为11.4万户，较7月20日减少336.0户，减幅为0.29%。在生物制品行业个股中，智飞生物股东户数高于行业平均水平，截至7月31日，生物制品行业平均股东户数为3.55万户。根据统计，智飞生物2026年7月20日至2026年7月31日，主力资金净流出2523.8万元，游资资金净流出1825.22万元，散户资金净流入4349.03万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700030366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU2580892789.USD","BK0196","LU1064130708.USD","BK0046","BK0239","300122","LU2580892862.HKD","LU1064131003.USD","BK0077","LU2148510915.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657950615","title":"智飞生物：CA111注射液处于一期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2657950615","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657950615?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:24","pubTimestamp":1786091049,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月07日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价进入低谷期，希望公司多披露一些信息，以便投资者更好了解公司的潜力，请问公司有哪些创新类药物？以及进展如何？有否对外授权合作的产品？智飞生物回复：您好，感谢您的关注和建议！公司通过北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地持续完善“预防&治疗”一体化布局。宸安生物研发的CA111注射液属于化学药品1类，目前处于一期临床试验阶段。公司在研管线详情请您查阅公司的信息披露。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700026798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","LU2580892789.USD","LU2148510915.USD","BK0077","LU2580892862.HKD","300122","BK0239","BK0196","LU1064131003.USD","BK0046","BK0188","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657615575","title":"智飞生物：截至2026年7月31日，公司普通股股东人数为114,012","url":"https://stock-news.laohu8.com/highlight/detail?id=2657615575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657615575?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:21","pubTimestamp":1786090882,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月07日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至7月底公司股东人数是多少，谢谢！智飞生物回复：您好，截至2026年7月31日，公司普通股股东人数为114,012，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700026475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0188","BK0046","LU1064130708.USD","BK0077","BK0239","BK0196","LU1328615791.USD","300122","LU2580892789.USD","LU2580892862.HKD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656935305","title":"股市必读：智飞生物新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656935305","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656935305?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:42","pubTimestamp":1785778933,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，智飞生物报收于13.23元，上涨1.46%，换手率1.4%，成交量19.74万手，成交额2.59亿元。公司公告汇总：截至2026年7月31日，智飞生物尚未实施股份回购，后续将根据市场情况推进并按规定披露进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","LU1064130708.USD","LU2580892789.USD","LU2580892862.HKD","LU2148510915.USD","BK0077","LU1064131003.USD","BK0239","LU1328615791.USD","300122","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656348618","title":"股市必读：智飞生物（300122）7月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2656348618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656348618?lang=zh_cn&edition=full","pubTime":"2026-08-03 01:05","pubTimestamp":1785690310,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，智飞生物报收于13.04元，上涨1.09%，换手率1.74%，成交量24.62万手，成交额3.19亿元。当日关注点交易信息汇总：7月31日主力资金净流入2032.86万元，占总成交额6.38%。交易信息汇总资金流向7月31日主力资金净流入2032.86万元，占总成交额6.38%；游资资金净流入241.15万元，占总成交额0.76%；散户资金净流出2274.01万元，占总成交额7.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","BK0239","LU1064130708.USD","LU1328615791.USD","300122","BK0196","LU1064131003.USD","LU2580892862.HKD","LU2580892789.USD","LU2148510915.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655355078","title":"智飞生物：聚焦糖尿病、肥胖等代谢类疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2655355078","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655355078?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:18","pubTimestamp":1785485902,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司是否有创新药研发或已经上市的产品？谢谢智飞生物回复：您好，公司通过北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地持续完善“预防&治疗”一体化布局。重庆宸安聚焦糖尿病、肥胖等代谢类疾病领域，围绕GLP-1类似物、胰岛素类似物等领域布局。同时，公司参股重庆智睿投资有限公司，积极布局大健康领域，促进前沿生物医药、先进生物技术的研发和产业化。公司的研发管线详情请您查阅公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100026145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","300122","BK0046","BK0188","LU2580892789.USD","LU2148510915.USD","LU1064130708.USD","LU2580892862.HKD","BK0077","LU1064131003.USD","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655355074","title":"智飞生物：宸安生物利拉鲁肽注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2655355074","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655355074?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:15","pubTimestamp":1785485710,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月31日在投资者关系平台上答复投资者关心的问题。智飞生物回复：您好，公司的控股子公司宸安生物聚焦糖尿病、肥胖等代谢类疾病领域，围绕GLP-1类似物、胰岛素类似物等领域布局。今年7月，宸安生物的利拉鲁肽注射液获批上市，详情请查阅公司披露在巨潮资讯网上的《关于公司自主产品利拉鲁肽注射液获得药品注册证书的公告》。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100025832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","LU2580892789.USD","LU1328615791.USD","300122","BK0188","LU2580892862.HKD","LU1064131003.USD","LU1064130708.USD","BK0077","BK0046","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700979","title":"智飞生物：截至2026年7月20日，公司普通股股东人数为114,348","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700979","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653700979?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:51","pubTimestamp":1784883078,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)07月24日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至7月10日和7月20日收盘公司股东人数分别是多少，谢谢！智飞生物回复：您好，截至2026年7月20日，公司普通股股东人数为114,348，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","BK0196","BK0188","LU2148510915.USD","BK0077","LU1064130708.USD","BK0239","LU1064131003.USD","LU2580892789.USD","LU1328615791.USD","300122","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652916297","title":"智飞生物最新公告：拟以1.5亿元至3亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2652916297","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652916297?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:50","pubTimestamp":1784544608,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司董事会审议通过回购股份方案，拟以自有或自筹资金不低于1.5亿元且不超过3亿元，通过集中竞价方式回购A股股份，用于股权激励或员工持股计划。回购价格不超过18.22元/股，实施期限为12个月。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000031727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0077","LU2580892789.USD","LU2580892862.HKD","LU1064130708.USD","LU1328615791.USD","BK0239","300122","LU2148510915.USD","BK0188","LU1064131003.USD","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652740939","title":"智飞生物：公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2652740939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652740939?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:03","pubTimestamp":1784279036,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)07月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，近期XG感染人数不断攀升，专家称病毒在不断进化逃避人体免疫系统屏障，而且在几年前接种XG疫苗人群的药效也在逐步归零，或需重新接种，请问公司目前最新相关疫苗产品都有哪些？智飞生物回复：您好，公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发。公司的研发管线详情请您查阅公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0188","LU2148510915.USD","BK0239","LU2580892862.HKD","BK0077","LU1064130708.USD","BK0196","LU1064131003.USD","LU2580892789.USD","LU1328615791.USD","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652409515","title":"智飞生物：开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652409515","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652409515?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278842,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月17日在投资者关系平台上答复投资者关心的问题。请介绍一下智飞生物回复：您好，公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发。同时，公司参股重庆智睿投资有限公司，积极布局大健康领域，促进前沿生物医药、先进生物技术的研发和产业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","300122","BK0196","LU1064130708.USD","LU2580892789.USD","LU2148510915.USD","BK0046","BK0239","BK0077","159646","BK0188","LU2580892862.HKD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652095584","title":"智飞生物：聚焦生产经营稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2652095584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652095584?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278834,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)07月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，作为行业龙头为什么贵司股价始终涨不过那些小公司？公司市值管理的相关措施有哪些？智飞生物回复：您好，自去年以来，公司聚焦生产经营稳健发展，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；同时完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0196","BK0046","LU1328615791.USD","BK0239","LU2580892789.USD","300122","LU2580892862.HKD","BK0188","BK0077","LU1064130708.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652240959","title":"智飞生物：自主产品涵盖预防流脑、流感等传染病的疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2652240959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652240959?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278833,"startTime":"0","endTime":"0","summary":"投资者提问：根据公开资料，公司6年前的股价曾到过231元，高股价是因为公司代理的默沙东疫苗当时在国内市场占有率高。如今，公司代理的默沙东疫苗市场逐步被国内的疫苗代替，公司股价6年间跌幅近97%。公司自主产品涵盖预防流脑、流感等传染病的疫苗和提供结核感染诊断、预防、治疗的生物制品，还涵盖用于成人2型糖尿病患者控制血糖等适应症的利拉鲁肽注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","LU1064131003.USD","BK0239","LU1328615791.USD","BK0077","300122","LU2580892862.HKD","LU1064130708.USD","BK0196","BK0046","BK0188","LU2580892789.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650184112","title":"智飞生物最新公告：控股子公司利拉鲁肽注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2650184112","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650184112?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:40","pubTimestamp":1783680014,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司控股子公司宸安生物的利拉鲁肽注射液(商品名：达舒宸)获得国家药监局颁发的药品注册证书，适用于成人2型糖尿病患者控制血糖，适用于降低伴有心血管疾病的2型糖尿病成人患者的主要心血管不良事件（心血管死亡、非致死性心肌梗死或非致死性卒中）风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000036393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU1328615791.USD","LU2148510915.USD","LU2580892862.HKD","300122","LU1064130708.USD","BK0196","LU1064131003.USD","LU2580892789.USD","BK0077","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786734276934,"stockEarnings":[{"period":"1week","weight":-0.0312},{"period":"1month","weight":0.0465},{"period":"3month","weight":-0.1316},{"period":"6month","weight":-0.2272},{"period":"1year","weight":-0.4262},{"period":"ytd","weight":-0.3079}],"compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0072},{"period":"3month","weight":-0.0503},{"period":"6month","weight":-0.0379},{"period":"1year","weight":0.0711},{"period":"ytd","weight":-0.0105}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"113869人(较上一季度减少0.13%)","perCapita":"12420股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}